Abstract

We have previously shown that rotavirus (RV) inner capsid protein VP6 has an adjuvant effect on norovirus (NoV) virus-like particle- (VLP-) induced immune responses and studied the adjuvant mechanism in immortalized cell lines used as antigen-presenting cells (APCs). Here, we investigated the uptake and presentation of RV VP6 and NoV GII.4 VLPs by primary bone marrow-derived dendritic cells (BMDCs). The adjuvant effect of VP6 on GII.4 VLP presentation and NoV-specific immune response induction by BMDC in vivo was also studied. Intracellular staining demonstrated that BMDCs internalized both antigens, but VP6 more efficiently than NoV VLPs. Both antigens were processed and presented to antigen-primed T cells, which responded by robust interferon γ secretion. When GII.4 VLPs and VP6 were mixed in the same pulsing reaction, a subpopulation of the cells had uptaken both antigens. Furthermore, VP6 copulsing increased GII.4 VLP uptake by 37% and activated BMDCs to secrete 2-5-fold increased levels of interleukin 6 and tumor necrosis factor α compared to VLP pulsing alone. When in vitro-pulsed BMDCs were transferred to syngeneic BALB/c mice, VP6 improved NoV-specific antibody responses. The results of this study support the earlier findings of VP6 adjuvant effect in vitro and in vivo.

Highlights

  • Rotavirus (RV) and norovirus (NoV) account for the majority of acute viral gastroenteritis (AGE) cases globally [1]

  • The adjuvant mechanism has been studied in immortalized cell lines used as antigenpresenting cells (APCs), namely, RAW macrophages and JAWSII dendritic cells (DCs), and the results suggested that VP6 acts as an immunomodulator and immunostimulator and facilitates NoV virus-like particles (VLPs) internalization by the APCs [23]

  • The bone marrow-derived dendritic cells (BMDCs) were frozen in CM containing 10% dimethyl sulfoxide (DMSO) until further use [48]

Read more

Summary

Introduction

Rotavirus (RV) and norovirus (NoV) account for the majority of acute viral gastroenteritis (AGE) cases globally [1]. Due to the challenges in propagation of NoV in cell culture, excluding live attenuated vaccines [4], NoV vaccine development is largely based on virus-like particles (VLPs) [3], which are spontaneously formed after the expression of NoV major capsid protein VP1 in vitro, e.g., in a baculovirus-insect cell expression system [5]. Immunogenic VP6 proteins can form various nanostructures in vitro [10], and VP6 has been suggested as the next-generation nonlive vaccine candidate against RV [11,12,13]. Our group has combined oligomeric VP6 nanostructures with NoV VLPs to generate nonlive subunit combination vaccine against NoV and RV [14, 15]

Methods
Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.